Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | Datamonitor Healthcare Reports | Bausch and Lomb's Contact Lens Solution Withdrawal - ReNu MultiPlus likely to struggle in attempt to regain market share

Bausch and Lomb's Contact Lens Solution Withdrawal - ReNu MultiPlus likely to struggle in attempt to regain market share

In May 2006 Bausch & Lomb's ReNu with MoistureLoc contact lens solution was permanently withdrawn from markets worldwide due to an outbreak of a fungal eye infection. For a large market player, the loss of a new revenue driver and the negative publicity surrounding the event is likely to have a significant impact on future success, as well as implications for other companies in the sector.

Scope

> This report analyzes the market outlook in the aftermath of the withdrawal of Bausch & Lomb's ReNu with MoistureLoc contact lens solution

> Datamonitor interviewed eight optometrists from the US and the EU in the course of research

Highlights

> Bausch & Lomb's explanation of the cause of infection is in line with suspicions of interviewed optometry experts that the revolutionary make-up of MoistureLoc's formula made it susceptible to external factors that could elevate infection risk.

> Moving forward, US practitioners will likely put more emphasis on patient adherence to particular recommended brands, and patients are likely to be less price-sensitive, favoring competitors over Bausch & Lomb's older contact lens solution, ReNu MultiPlus.

> Collateral damage to Bausch & Lomb's eye care franchise in European markets is expected to be minimal.

Reasons to Purchase

> Understand the implications of Bausch & Lomb's product recall through in-depth analysis based on interviews with leading experts

> Anticipate likely changes in the future market dynamics for contact lens solutions following the withdrawal of ReNu with MoistureLoc

29-Aug-06 PDF 12
Table of Contents
Price: $3,800.00 / €2,539.92

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions